In the last trading session, 1.95 million Vincerx Pharma Inc (NASDAQ:VINC) shares changed hands as the company’s beta touched 1.23. With the company’s per share price at $0.18 changed hands at -$0.01 or -5.89% during last session, the market valuation stood at $6.52M. VINC’s last price was a discount, traded about -5105.56% off its 52-week high of $9.37. When we look at Vincerx Pharma Inc’s average trading volume, we note the 10-day average is 40.58 million shares, with the 3-month average coming to 6.97 million.
Analysts gave the Vincerx Pharma Inc (VINC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended VINC as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Vincerx Pharma Inc’s EPS for the current quarter is expected to be 0.
Vincerx Pharma Inc (NASDAQ:VINC) trade information
Instantly VINC was in red as seen at the end of in last trading. With action -22.39%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -31.93%, with the 5-day performance at -22.39% in the red. However, in the 30-day time frame, Vincerx Pharma Inc (NASDAQ:VINC) is -16.75% down. Looking at the short shares, we see there were 0.42 million shares sold at short interest cover period of 0.77 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2, meaning bulls need an upside of 91.0% from its current market value. According to analyst projections, VINC’s forecast low is 2 with 2 as the target high. To hit the forecast high, the stock’s price needs a -1011.11% plunge from its current level, while the stock would need to soar -1011.11% for it to hit the projected low.
Vincerx Pharma Inc (VINC) estimates and forecasts
Data shows that the Vincerx Pharma Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -74.18% over the past 6 months, a 60.85% in annual growth rate that is considerably higher than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -283.70%. The 2025 estimates are for Vincerx Pharma Inc earnings to increase by 59.79%.
VINC Dividends
Vincerx Pharma Inc is expected to release its next quarterly earnings report in February.
Vincerx Pharma Inc (NASDAQ:VINC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 15.81% of Vincerx Pharma Inc shares while 24.40% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 28.98%. There are 24.40% institutions holding the Vincerx Pharma Inc stock share, with PROSIGHT MANAGEMENT, LP the top institutional holder. As of 2024-06-30, the company held 11.6281% of the shares, roughly 2.49 million VINC shares worth $2.02 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 9.2897% or 1.99 million shares worth $1.61 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . With 341.07 shares estimated at $61017.0 under it, the former controlled 1.01% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.83% of the shares, roughly 280.42 shares worth around $50166.0.
